Carl June will discuss the emergence of a new form of targeted immunotherapy that enhances the patient’s own T lymphocytes to attack cancer. This type of cell-based, targeted immunotherapy has become one of the most exciting new approaches to treating cancer, stimulating the biotechnology and pharma industries to develop the means to deliver this therapy to patients. June is a professor of pathology and laboratory medicine at the Perelman School of Medicine and director of translational research, Abramson Cancer Center at the University of Pennsylvania. More information is online here.